TABLE 2.
Percentage of responses on duration or dose of different pharmacological agents
| Remdesivir | 5‐10 d depending on severity | 5 d | 10 d | >10 d | |
| 56.6% | 40.6% | 2.6% | 0.2% | ||
| Favipiravir | <7 d | 7‐14 d | >14 d | ||
| 28.6% | 69.6% | 1.8% | |||
| Ivermectin | 1 dose | 1‐3 d | >3days | ||
| 4.1% | 65.2% | 30.7% | |||
| Interferon | <5 d | 5‐10 d | >10 d | ||
| 58.6% | 38.2% | 3.3% | |||
| Convalescent plasma | 1 session | 2 session | >2 session | ||
| 66.3% | 26.9% | 6.9% | |||
| Corticosteroids duration | <5 d | 5‐10 d | >10 d | >10 d based on laboratory markers a | |
| 9.6% | 45.9% | 13.3% | 50.2% | ||
| Corticosteroids type | Hydrocortisone | Dexamethasone | Methylprednisolone | Prednisolone | Any corticosteroid |
| 1.9% | 44.1% | 50.2% | 1.5% | 2.3% | |
| Corticosteroids dose b | 8 mg | 9‐16 mg | >16 mg | ||
| 70.1% | 20.6% | 9.3% | |||
| Tocilizumab | 1 dose | 2 doses | >2 doses | ||
| 39.5% | 57.2% | 3.3% | |||
| Itolizumab | 1 dose | 2 doses | >2 doses | ||
| 47.2% | 45.3% | 7.5% |
a
Extended duration based on the clinical response and inflammatory biomarkers.
b
Corticosteroid dose in equivalent of dexamethasone phosphate.